<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090671</url>
  </required_header>
  <id_info>
    <org_study_id>MDP2018</org_study_id>
    <nct_id>NCT04090671</nct_id>
  </id_info>
  <brief_title>Evaluation of the Multidimensional Dyspnea Profile (MDP)</brief_title>
  <official_title>Das Multidimensionale Dyspnoe Profil (MDP) Bei COPD, Herzinsuffizienz Und Schlafapnoe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pneumologie Hagen Ambrock eV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pneumologie Hagen Ambrock eV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this multicenter prospective cohort study is the evaluation of the multidimensional
      qualities of dyspnea in a number of diseases using the Multidimensional Dyspnea Profile
      (Banzett et al, ERJ 2015).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study sites will examine patients with COPD (Chronic obstructive pulmonary disease) in
      state of acute exacerbation and in stable state, patients with congestive heart failure (CHF)
      in state of acute decompensated cardiac insufficiency, and patients newly diagnosed with
      obstructive sleep apnea (OSA) as a control group.

      In the acute setting of COPD and CHF, the questionnaire will be given at the day of hospital
      admission and at the day of discharge. The patients will additionally fill the Severe
      Respiratory Insufficiency (SRI) Questionnaire (in COPD) or the Physical Activity
      Questionnaire 50+ (in CHF).

      In stable state of COPD, the questionnaires will be given once during a routine control visit
      at the hospital or the medical practice.

      In OSA, the questionnaire will be given once during the first visit in the sleep laboratory.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter prospective cohort study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MDP scores during hospital stay</measure>
    <time_frame>day 1 to day 5</time_frame>
    <description>A1, Scale: Scale about breathing sensations with a defined start- and endpoint (neutral - unbearable). Values reach from 0—10, and higher values represent a worse outcome.
SQ1 (sensoric quality), Choice: 5 Phrases and terms about breathing sensations. Choose between yes and no and select one as &quot;most accurately&quot;.
SQ2 (sensoric quality), Scales: 5 subscales about intensity of breathing sensations (muscle work; air hunger; chest tightness; mental effort; breathing a lot) with defined start- and endpoints (none - as intense as imaginable). Values reach from 0 - 10, and higher values represent a worse outcome.
A2 (emotional quality), Scales: 5 subscales about emotions (depressed, anxious, frustrated, angry, afraid) with defined start- and endpoints (none - as intense as imaginable). Values reach from 0 - 10, and higher values represent a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of MDP scores with clinical data</measure>
    <time_frame>1 to 5 (+- 3) days</time_frame>
    <description>comparison of the A1 and A2 (scale 0-10) and SQ2 (scale 0-10) scores of the MDP between the diseases, the evaluation of dependencies of clinical routine data with the MDP scores</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COPD Exacerbation</condition>
  <condition>CHF</condition>
  <condition>OSA</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD Exacerbation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In stable state of COPD, the questionnaire MDP will be administered once during a routine control visit at the hospital or the medical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The questionnaire MDP will be administered once during the first visit in the sleep laboratory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multidimensional Dyspnea Profile</intervention_name>
    <description>The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.</description>
    <arm_group_label>CHF</arm_group_label>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_label>COPD Exacerbation</arm_group_label>
    <arm_group_label>OSA</arm_group_label>
    <other_name>MDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients with acute exacerbation (Group I)

          -  CHF patients with acute decompensation (group II)

          -  stable COPD patients (group III)

          -  OSA patients with AHI&gt;15 (group IV)

        Exclusion Criteria:

          -  Other severe acute diseases that contradict the participation in a clinical trial

          -  Simultaneous participation in another clinical trial

          -  Not capable of giving consent

          -  Language abilities and other disabilities that contradicts the understanding or
             completing of a clinical questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Nilius, Prof.Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>KEM Kliniken Essen-Mitte</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg Nilius, Prof.Dr.med</last_name>
    <phone>0049 (0) 201 174</phone>
    <phone_ext>22000</phone_ext>
    <email>g.nilius@kem-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrike Domanski</last_name>
    <phone>0049 (0) 2331 974</phone>
    <phone_ext>2080</phone_ext>
    <email>ulrike.domanski@helios-gesundheit.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft gGmbH</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Nilius, Prof.Dr.med</last_name>
      <phone>0049 (0) 201 174</phone>
      <phone_ext>22000</phone_ext>
      <email>g.nilius@kem-med.com</email>
    </contact>
    <contact_backup>
      <last_name>Ulrike Domanski</last_name>
      <phone>0049 (0) 2331 974</phone>
      <phone_ext>2080</phone_ext>
      <email>ulrike.domanski@helios-gesundheit.de</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Stump</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinik Hagen Ambrock</name>
      <address>
        <city>Hagen</city>
        <state>NRW</state>
        <zip>58091</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Galetke, Prof.Dr.med.</last_name>
      <phone>0049 2331 974</phone>
      <phone_ext>2000</phone_ext>
      <email>wolfgang.galetke@helios-gesundheit.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrike Domanski</last_name>
      <phone>0049 (0) 2331 974</phone>
      <phone_ext>2080</phone_ext>
      <email>ulrike.domanski@helios-gesundheit.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Märkische Kliniken GmbH, Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <state>NRW</state>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Josef Franke, PD Dr.med</last_name>
      <phone>0049 2351 46</phone>
      <phone_ext>3361</phone_ext>
      <email>Karl-Josef.Franke@Klinikum-Luedenscheid.de</email>
    </contact>
    <contact_backup>
      <last_name>Bald</last_name>
      <phone>0049 2351 46</phone>
      <phone_ext>3361</phone_ext>
      <email>Markus.Bald@klinikum-luedenscheid.de</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Bald</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med V. Jansen</name>
      <address>
        <city>Menden</city>
        <state>NRW</state>
        <zip>58706</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Jansen, MD</last_name>
      <phone>0049 (0) 2373</phone>
      <phone_ext>3234</phone_ext>
      <email>info@lungenarzt-menden.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrike Domanski</last_name>
      <phone>0049 (0) 2331 974</phone>
      <phone_ext>2080</phone_ext>
      <email>ulrike.domanski@helios-gesundheit.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kliniken Essen-Mitte</investigator_affiliation>
    <investigator_full_name>Georg Nilius, PD DR med</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Dyspnoea</keyword>
  <keyword>MDP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

